Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

The link between dopamine function and apathy in cannabis users: an [18F]-DOPA PET imaging study.

Bloomfield MA, Morgan CJ, Kapur S, Curran HV, Howes OD.

Psychopharmacology (Berl). 2014 Jun;231(11):2251-9. doi: 10.1007/s00213-014-3523-4. Epub 2014 Apr 3.

PMID:
24696078
2.

Dopaminergic function in cannabis users and its relationship to cannabis-induced psychotic symptoms.

Bloomfield MA, Morgan CJ, Egerton A, Kapur S, Curran HV, Howes OD.

Biol Psychiatry. 2014 Mar 15;75(6):470-8. doi: 10.1016/j.biopsych.2013.05.027. Epub 2013 Jun 29.

PMID:
23820822
3.

Dopamine function in cigarette smokers: an [¹⁸F]-DOPA PET study.

Bloomfield MA, Pepper F, Egerton A, Demjaha A, Tomasi G, Mouchlianitis E, Maximen L, Veronese M, Turkheimer F, Selvaraj S, Howes OD.

Neuropsychopharmacology. 2014 Sep;39(10):2397-404. doi: 10.1038/npp.2014.87. Epub 2014 Apr 10.

4.

Dopamine response to psychosocial stress in chronic cannabis users: a PET study with [11C]-+-PHNO.

Mizrahi R, Suridjan I, Kenk M, George TP, Wilson A, Houle S, Rusjan P.

Neuropsychopharmacology. 2013 Mar;38(4):673-82. doi: 10.1038/npp.2012.232. Epub 2012 Nov 8.

5.

Net influx of plasma 6-[18F]fluoro-L-DOPA (FDOPA) to the ventral striatum correlates with prefrontal processing of affective stimuli.

Siessmeier T, Kienast T, Wrase J, Larsen JL, Braus DF, Smolka MN, Buchholz HG, Schreckenberger M, Rösch F, Cumming P, Mann K, Bartenstein P, Heinz A.

Eur J Neurosci. 2006 Jul;24(1):305-13.

PMID:
16882026
6.

Dopamine synthesis capacity in patients with treatment-resistant schizophrenia.

Demjaha A, Murray RM, McGuire PK, Kapur S, Howes OD.

Am J Psychiatry. 2012 Nov;169(11):1203-10.

PMID:
23034655
7.

Stress-induced dopamine response in subjects at clinical high risk for schizophrenia with and without concurrent cannabis use.

Mizrahi R, Kenk M, Suridjan I, Boileau I, George TP, McKenzie K, Wilson AA, Houle S, Rusjan P.

Neuropsychopharmacology. 2014 May;39(6):1479-89. doi: 10.1038/npp.2013.347. Epub 2013 Dec 24.

8.

The test-retest reliability of 18F-DOPA PET in assessing striatal and extrastriatal presynaptic dopaminergic function.

Egerton A, Demjaha A, McGuire P, Mehta MA, Howes OD.

Neuroimage. 2010 Apr 1;50(2):524-31. doi: 10.1016/j.neuroimage.2009.12.058. Epub 2009 Dec 23.

9.

Elevated striatal dopamine function linked to prodromal signs of schizophrenia.

Howes OD, Montgomery AJ, Asselin MC, Murray RM, Valli I, Tabraham P, Bramon-Bosch E, Valmaggia L, Johns L, Broome M, McGuire PK, Grasby PM.

Arch Gen Psychiatry. 2009 Jan;66(1):13-20. doi: 10.1001/archgenpsychiatry.2008.514.

PMID:
19124684
10.

Dopamine release in chronic cannabis users: a [11c]raclopride positron emission tomography study.

Urban NB, Slifstein M, Thompson JL, Xu X, Girgis RR, Raheja S, Haney M, Abi-Dargham A.

Biol Psychiatry. 2012 Apr 15;71(8):677-83. doi: 10.1016/j.biopsych.2011.12.018. Epub 2012 Jan 29.

11.

Striatal D(2)/D(3) receptor availability is inversely correlated with cannabis consumption in chronic marijuana users.

Albrecht DS, Skosnik PD, Vollmer JM, Brumbaugh MS, Perry KM, Mock BH, Zheng QH, Federici LA, Patton EA, Herring CM, Yoder KK.

Drug Alcohol Depend. 2013 Feb 1;128(1-2):52-7. doi: 10.1016/j.drugalcdep.2012.07.016. Epub 2012 Aug 19.

12.

Decreased spontaneous eye blink rates in chronic cannabis users: evidence for striatal cannabinoid-dopamine interactions.

Kowal MA, Colzato LS, Hommel B.

PLoS One. 2011;6(11):e26662. doi: 10.1371/journal.pone.0026662. Epub 2011 Nov 18.

13.

Presynaptic striatal dopamine dysfunction in people at ultra-high risk for psychosis: findings in a second cohort.

Egerton A, Chaddock CA, Winton-Brown TT, Bloomfield MA, Bhattacharyya S, Allen P, McGuire PK, Howes OD.

Biol Psychiatry. 2013 Jul 15;74(2):106-12. doi: 10.1016/j.biopsych.2012.11.017. Epub 2013 Jan 8.

PMID:
23312565
14.

Cerebral glucose metabolism and D2/D3 receptor availability in young adults with cannabis dependence measured with positron emission tomography.

Sevy S, Smith GS, Ma Y, Dhawan V, Chaly T, Kingsley PB, Kumra S, Abdelmessih S, Eidelberg D.

Psychopharmacology (Berl). 2008 May;197(4):549-56. doi: 10.1007/s00213-008-1075-1. Epub 2008 Feb 13.

PMID:
18270689
15.

Complementary positron emission tomographic studies of the striatal dopaminergic system in Parkinson's disease.

Antonini A, Vontobel P, Psylla M, Günther I, Maguire PR, Missimer J, Leenders KL.

Arch Neurol. 1995 Dec;52(12):1183-90.

PMID:
7492293
16.

Striatal and extrastriatal dopamine transporter in cannabis and tobacco addiction: a high-resolution PET study.

Leroy C, Karila L, Martinot JL, Lukasiewicz M, Duchesnay E, Comtat C, Dollé F, Benyamina A, Artiges E, Ribeiro MJ, Reynaud M, Trichard C.

Addict Biol. 2012 Nov;17(6):981-90. doi: 10.1111/j.1369-1600.2011.00356.x. Epub 2011 Aug 4.

PMID:
21812871
17.

Dopaminergic mechanisms of reduced basal ganglia responses to hedonic reward during interferon alfa administration.

Capuron L, Pagnoni G, Drake DF, Woolwine BJ, Spivey JR, Crowe RJ, Votaw JR, Goodman MM, Miller AH.

Arch Gen Psychiatry. 2012 Oct;69(10):1044-53. doi: 10.1001/archgenpsychiatry.2011.2094.

18.
19.

[18F]MK-9470 PET measurement of cannabinoid CB1 receptor availability in chronic cannabis users.

Ceccarini J, Kuepper R, Kemels D, van Os J, Henquet C, Van Laere K.

Addict Biol. 2015 Mar;20(2):357-67. doi: 10.1111/adb.12116. Epub 2013 Dec 27.

PMID:
24373053
20.

Personality correlates of [18F]dopa striatal uptake: results of positron-emission tomography in Parkinson's disease.

Menza MA, Mark MH, Burn DJ, Brooks DJ.

J Neuropsychiatry Clin Neurosci. 1995 Spring;7(2):176-9.

PMID:
7626960
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk